Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibromyalgia | 9 | 2019 | 30 | 1.680 |
Why?
|
| Cognition Disorders | 2 | 2015 | 985 | 0.450 |
Why?
|
| Attention | 2 | 2015 | 124 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 892 | 0.300 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2016 | 258 | 0.280 |
Why?
|
| Cognition | 1 | 2015 | 1337 | 0.260 |
Why?
|
| Citrulline | 2 | 2016 | 6 | 0.260 |
Why?
|
| Aggrecans | 2 | 2016 | 54 | 0.250 |
Why?
|
| Brain | 1 | 2015 | 1658 | 0.240 |
Why?
|
| Memory, Short-Term | 1 | 2006 | 96 | 0.240 |
Why?
|
| Arthritis, Experimental | 2 | 2016 | 50 | 0.230 |
Why?
|
| Memory Disorders | 1 | 2006 | 158 | 0.230 |
Why?
|
| Rheumatology | 4 | 2019 | 85 | 0.210 |
Why?
|
| Pain Measurement | 2 | 2019 | 484 | 0.160 |
Why?
|
| Epitopes | 2 | 2016 | 44 | 0.160 |
Why?
|
| Symptom Assessment | 2 | 2016 | 19 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2019 | 135 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2010 | 190 | 0.140 |
Why?
|
| Self Report | 2 | 2016 | 223 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 1197 | 0.130 |
Why?
|
| Humans | 15 | 2019 | 27205 | 0.130 |
Why?
|
| Prognosis | 3 | 2015 | 805 | 0.130 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 14 | 0.130 |
Why?
|
| Proteoglycans | 1 | 2016 | 133 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 478 | 0.130 |
Why?
|
| Patient Participation | 1 | 2016 | 48 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 44 | 0.110 |
Why?
|
| Female | 10 | 2019 | 15296 | 0.100 |
Why?
|
| Prevalence | 1 | 2015 | 455 | 0.100 |
Why?
|
| Memory | 1 | 2015 | 295 | 0.100 |
Why?
|
| Quality of Life | 2 | 2015 | 634 | 0.100 |
Why?
|
| Male | 9 | 2019 | 14849 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2016 | 416 | 0.090 |
Why?
|
| Hydrazines | 1 | 2010 | 7 | 0.090 |
Why?
|
| Benzoates | 1 | 2010 | 5 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2010 | 61 | 0.080 |
Why?
|
| Adult | 6 | 2016 | 7916 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 1155 | 0.080 |
Why?
|
| Middle Aged | 7 | 2019 | 9031 | 0.070 |
Why?
|
| Plasmapheresis | 1 | 2007 | 13 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 27 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 350 | 0.060 |
Why?
|
| Data Collection | 1 | 2006 | 90 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2016 | 110 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 56 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 99 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2016 | 148 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2016 | 589 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2016 | 179 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 483 | 0.050 |
Why?
|
| Mice | 2 | 2016 | 1413 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 90 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 1781 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 3645 | 0.030 |
Why?
|
| Spleen | 1 | 2016 | 32 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 91 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 154 | 0.030 |
Why?
|
| Complex Mixtures | 1 | 2016 | 3 | 0.030 |
Why?
|
| Tissue Extracts | 1 | 2016 | 9 | 0.030 |
Why?
|
| Arginine | 1 | 2016 | 17 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2016 | 25 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 62 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 57 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 123 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 524 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 374 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 233 | 0.030 |
Why?
|
| Aged | 3 | 2015 | 9076 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 23 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 260 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 679 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 1803 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 266 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 17 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 101 | 0.030 |
Why?
|
| Histones | 1 | 2013 | 32 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 144 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 147 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 55 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 84 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 142 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 86 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 200 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 210 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 175 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 2016 | 330 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2010 | 2 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 8 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2010 | 25 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2010 | 36 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 604 | 0.020 |
Why?
|
| United States | 1 | 2016 | 2056 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 3542 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 488 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 760 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 260 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 200 | 0.020 |
Why?
|
| Kidney | 1 | 2007 | 153 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 127 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1896 | 0.010 |
Why?
|